Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Angiotensin-Converting Enzyme Gene Deletion Polymorphism, Risk Factor for Lacune, not Carotid Atheroma
Stroke 26:1329-1333, Markus,H.S.,et al, 1995
The Use of Sumatriptan in Patients with Monoamine Oxidase Inhibitors
Neurol 45:1039-1040, Diamond,S., 1995
Clinicopath Conf
Intravascular Lymphomatosis, Case 31-1995, NEJM 333:992-999995., , 1995
Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer's Disease
JAMA 271:992-998, Watkins,P.B.,et al, 1994
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Clinicopath Conf
Primary Malignant Lymphoma of CNS, Diffuse, Large-Cell]B-Cell Type, Case 36-1994, NEJM 331:861-8684., , 1994
Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
J Clin Psychiatry 55:38-45, DeVane,C.L., 1994
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Neurosarcoidosis:Progress and Clinical Aspects
Neurol 43:8-12, Scott,T.F., 1993
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
Deprenyl Effects of Levodopa Pharmacodynamics, Mood, and Free Radical Scavenging
Neurol 42:541-544, Baronti,F.,et al, 1992
Sarcoidosis of the Nervous System, A Clinical Approach
Arch Int Med 151:1317-1321, Sharma,Om.P.&Sharma,A.D., 1991
Tacrine in Alzheimer's Disease
Lancet 337:989-992, Eagger,S.A.,et al, 1991
Neurosarcoidosis:Signs, Course and Treatment in 35 Confirmed Cases
Medicine 69:261-276, Chapelon,C.,et al, 1990
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Long-Term Efficacy and Safety of Deprenyl (Selegiline) in Advanced Parkinson's Disease
Neurol 39:1109-1111, Golbe,L.I.,et al, 1989
Selegiline Use to Prevent Progression of Parkinson's Disease
Arch Neurol 46:1275-1279, Elizan,T.S.,et al, 1989
MPTP:A Neurotoxin Relevant to the Pathophysiology of Parkinson's Disease, The 1985 George Cotzias Lecture
Neurol 36:250-258, Snyder,S.H.&D'Amato,R.J., 1986
Pyridoxine Deficiency & Peripheral Neuropathy Associated with Long-Term Phenelzine Therapy
Am J Med 75:887-888, Heller,C.A.,et al, 1983
Deprenyl In Parkinson's Disease
Lancet 2:695-696, , 1982
Deprenyl in Parkinson Disease
Neurol 31:19-23, Eisler,T.,et al, 1981
Reduction of Angiotensin-Converting Enzyme in Substantia Nigra in Early-Onset Schizophrenia
NEJM 300:502-503, Arregui,A.,et al, 1979
Clofibrate-Induced Muscle Damage with Myoglobinuria & Cardiomyopathy
NEJM 296:942, Smals,A.G.H., 1977
Purine Phosphoribosyltransferase in Gilles de la Tourette Syndrome
NEJM 296:210, VanWoert,M.H.,et al, 1977
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976
Elevation of Serum Angiotension-Converting-Enzyme (ACE) Level in Sarcoidosis
Am J Med 59:365-372, Lieberman,J., 1975
Effect of Chronic Anticonvulsant Therapy on Serum 25-Hydroxycalciferol Levels in Adults
NEJM 287:898, Hahn,T.,et al, 1972
Monoamine Oxidase Inhibitor & L-Dopa
BMJ 3:388, Hunter,H.R.,et al, 1970
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Efficacy and Safety of Selimetinib in Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas (KOMET): A Multcentre, International, Randomised Placebo-Controlled, Parallel, Double-Blind, Phase 3 Study
Lancet 405:2217-2230, Chen,A.P.,et al, 2025
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
Clinicopathologic Conference, Lyme Carditis
NEJM 393:799-807, Case 24-2025, 2025
A 32-Year-Old Woman Presenting with Thunderclap Headache in the Third Trimester
Neurol 105:e214029, Kuczynski,A.M. & Kingston,W.S., 2025
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Clinicopathologic Conference, Metastatic Small-Cell Carcinoma of the Lung
NEJM 392:903-914, Case 7-2025, 2025
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System:A Multicentric Cohort Study
Ann Neurol 97:435-448, Berthet,E.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
NEJM 390:1745-1755, 1815, Connolly,S.J.,et al, 2024
Mechanical Thrombectomy in Anticoagulated Patients with Acute Ischemic Stroke, A Meta-Analysis
Neurologist 29:194-203, Zhang,H.L.,et al, 2024
A Young Woman With Hypertonia, Severe Scoliosis, and Encephalopathy
JAMA Neurol 81:83-84, Hua,L.,et al, 2024
Clinicopatholigical Conference, Plasmodium Falciparum Malaria
NEJM 309:549-556, Case 4-2024, 2024
A 54-Year-Old Woman with Progressive Headache and Neurologic Decline
Neurol 102:e209190, Cheng,Y. & Zachariah,J., 2024